test
NOA-09 (CeTeG)
NOA-09 (CeTeG)
Lomustine-temozolomide Combination Therapy versus Standard Temozolomide Therapy in Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CeTeG/NOA–09): A Randomised, Open-label, Phase 3 Trial
test
Lomustine-temozolomide Combination Therapy versus Standard Temozolomide Therapy in Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CeTeG/NOA–09): A Randomised, Open-label, Phase 3 Trial